Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the united states

Background: Both novel hormonal therapies and docetaxel are approved for treatment of metastatic prostate cancer (mPC, in castration sensitive or refractory settings). Present knowledge gaps include lack of real-world data on treatment patterns in patients with newly diagnosed mPC, and comparative effectiveness of novel hormonal therapies (NHT) versus docetaxel after treatment with a prior NHT. Methods: Herein we extracted patient-level data from a large real-world database of patients with mPC in United States. Utilization of NHT or docetaxel for mPC and comparative effectiveness of an alternate NHT versus docetaxel after one prior NHT was evaluated. Comparative effectiveness was examined via Cox proportional hazards model with propensity score matching weights. Each patient’s propensity for treatment was modeled via random forest based on 22 factors potentially driving treatment selection. Results: The majority of patients (54%) received only androgen deprivation therapy for mPC. In patients treated with an NHT, alternate NHT was the most common next therapy and was associated with improved median overall survival over docetaxel (abiraterone followed by docetaxel vs. enzalutamide (8.7 vs. 15.6 months, adjusted hazards ratio, aHR 1.32, p = 0.009, and enzalutamide followed by docetaxel vs. abiraterone (9.7 vs. 13.2 months aHR 1.40, p = 0.009). Limitations of the study include retrospective design.